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Abstract
Background: Arthritis (or compression) gloves are widely prescribed to people with rheumatoid arthritis and other
forms of hand arthritis. They are prescribed for daytime wear to reduce hand pain and improve hand function, and/
or night-time wear to reduce pain, improve sleep and reduce morning stiffness. However, evidence for their
effectiveness is limited. The aims of this study were to investigate the clinical and cost effectiveness of arthritis
gloves compared to placebo gloves on hand pain, stiffness and function in people with rheumatoid arthritis and
persistent hand pain.
Methods: A parallel randomised controlled trial, in adults (≥ 18 years) with rheumatoid or undifferentiated
inflammatory arthritis at 16 National Health Service sites in the UK. Patients with persistent hand pain affecting function
and/or sleep were eligible. Randomisation (1:1) was stratified by recent change (or not) in medication, using permuted
blocks of random sizes. Three-quarter-finger length arthritis gloves (Isotoner®: applying 23-32mmHg pressure)
(intervention) were compared to loose-fitting placebo gloves (Jobskin® classic: providing no/minimal pressure)
(control). Both gloves (considered to have similar thermal qualities) were provided by occupational therapists. Patients
and outcome assessors were blinded; clinicians were not. The primary outcome was dominant hand pain on activity
(0–10) at 12 weeks, analysed using linear regression and intention to treat principles.
Results: Two hundred six participants were randomly assigned (103 per arm) and 163 (84 intervention: 79 control) completed
12-week follow-up. Hand pain improved by 1.0 (intervention) and 1.2 (control), an adjusted mean difference of 0.10 (95%CI: −
0.47 to 0.67; p = 0.72). Adverse events were reported by 51% of intervention and 36% of control group participants; with 6 and
7% respectively, discontinuing glove wear. Provision of arthritis gloves cost £129, with no additional benefit.
Conclusion: The trial provides evidence of no clinically important effect of arthritis gloves on any of the trial outcomes (hand
pain, function and stiffness) and arthritis gloves are not cost-effective. The clinical and cost-effectiveness results support ceasing
provision of arthritis gloves in routine clinical practice. Funding: National Institute for Health Research.
Trial registration: ISRCTN, ISRCTN25892131; Registered 05/09/2016: retrospectively registered.
Keywords: Rheumatoid arthritis, Rehabilitation, Hand, Pain, Orthotic devices, Clinical trial
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: A.hammond@salford.ac.uk
1Centre for Health Sciences Research, School of Health and Society,
University of Salford, Allerton Building, Frederick Road, Salford M6 6PU, UK
Full list of author information is available at the end of the article
Hammond et al. BMC Musculoskeletal Disorders           (2021) 22:47 
https://doi.org/10.1186/s12891-020-03917-8
Introduction
Rheumatoid arthritis (RA) affects 1% of the world’s
population [1]. Disease modifying anti-rheumatic drugs
(DMARDs) are prescribed as soon as possible to control
symptoms, including to those with persistent synovitis
where other pathologies are ruled out but not yet meet-
ing criteria for RA, i.e. undifferentiated inflammatory
arthritis (UIA). Functional ability can still deteriorate
even though disease activity is controlled [2]. Over 90%
of people with RA and UIA report hand symptoms of
pain, stiffness, muscle weakness, paraesthesia, and diffi-
culty making a fist [3]. Most have bilateral hand symp-
toms, resulting in difficulties with work, everyday
activities and leisure.
Arthritis gloves (or compression gloves) have been
commonly prescribed since the 1980’s for people with
RA and UIA in the United Kingdom (UK), North Amer-
ica and Europe [4–7]. A survey of occupational thera-
pists in the UK identified that the most common model
and make prescribed are three-quarter length finger Iso-
toner® gloves (Fig. 1) [4]. They are prescribed for day-
time wear to reduce hand pain and improve hand
function, and/or night-time wear to reduce pain, im-
prove sleep and reduce morning stiffness [4, 5]. The sec-
ond most common are three-quarter length finger
oedema gloves, of which there are several makes avail-
able [4]. The mechanism whereby arthritis gloves are
thought to impact on hand symptoms is through com-
pression, which: removes extracellular fluid, thus redu-
cing pain, stiffness and improving finger movement; and
increases blood flow, thus increasing warmth and redu-
cing pain [6, 7]. In clinical practice, therapists ensure a
“snug fit” around the proximal interphalangeal joints
(PIPJs), metacarpophalangeal joints (MCPJs) and across
the dorsum of the hand, i.e. to ensure enough compres-
sion is applied without restricting circulation to the fin-
gers or causing pins and needles. It is unclear what a
therapeutic level of compression is, as no physiological
studies have been conducted. Manufacturers of com-
monly prescribed glove makes report pressures of 15 to
32mmHg [8, 9]. The amount of compression applied de-
pends on: the amount of elastane in the glove fabric; the
individual’s hand size and shape; and the glove fit. Isoto-
ner® gloves have the highest amount of elastane content
of those currently on the market. According to the man-
ufacturers’ specifications, Isotoner® gloves exert the high-
est pressure [8, 9].
Arthritis gloves are considered a comparatively low-
cost, quickly provided treatment for pain relief, although
they are a recurrent cost as they need replacing every
six-months. Gloves are also commonly prescribed to
people with other forms of inflammatory arthritis and
with hand osteoarthritis. The global market for arthritis
gloves is rising [10] and millions of people with hand
arthritis worldwide purchase these gloves for themselves.
Systematic review evidence is inconclusive about the
effectiveness of arthritis gloves [5]. Previous trials were
small (n = 8 to 24), evaluated a variety of full-length
finger arthritis gloves in RA for night-time use only [6,
7, 11–13], and had moderate to high risk of bias [5].
Three trials, with moderate risk of bias, showed signifi-
cant reductions in PIPJ circumference. However, this
was only 0.7 to 1.15 mm and it is questionable what the
benefits of this were [5]. Trials were inconclusive about
effects on nocturnal hand pain, morning stiffness and
hand swelling. No benefits were identified in range of
motion, dexterity, grip and pinch strength [5]. One trial
found arthritis gloves and thermal gloves had similar ef-
fects in reducing nocturnal hand pain and hand stiff-
ness [6]. Gloves’ effect on day-time hand pain, the most
common reason for prescription nowadays, has not
been evaluated.
We conducted a pre-test post-test feasibility trial to
evaluate Isotoner® arthritis gloves, over a four-week
period, in people with RA and UIA in 10 Rheumatology
occupational therapy departments. In this we: developed
a treatment manual, based on therapists’ expertise in
providing arthritis gloves, to standardise delivery; devel-
oped an arthritis glove information sheet for partici-
pants; developed and tested trial procedures; identified
the most relevant outcome measure considered by par-
ticipants was day-time hand pain; and that this and
other secondary outcomes deemed most relevant were
self-report and therefore collectable using reliable, valid
patient reported outcome measures. Participants re-
ported they liked the warmth, comfort and gentle sup-
port provided by the arthritis gloves [14]. The results of
this trial indicated that the procedures were feasible and
there were some improvements in hand pain, stiffness
and function, with the caveat that there was no control
group. This supported the need for a definitive trial.
Fig. 1 Intervention (Isotoner®) Arthritis Glove
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We sought the input of our clinical stakeholders, par-
ticipating therapists and our patient and public involve-
ment (PPI) representatives throughout this research. We
conducted a series of focus groups to discuss the feasi-
bility study results and design the A-Gloves trial, to en-
sure it would be acceptable to both patients and
participating clinicians. We discussed what the compara-
tor intervention should be: usual care; ordinary gloves
plus usual care; or placebo gloves plus usual care. Our
patient research partners emphasised the importance of
comparing arthritis gloves with placebo gloves, and that
these should be credible (i.e. another model of arthritis
glove which was loosely fitted to apply no pressure but
provide similar warmth) to ensure that the effects of
wearing a “medical device” were controlled for. We dis-
cussed the length of follow-up required. The PPI group
and therapists emphasised glove wear should increase
gradually over the first few weeks, in order to become
accustomed to glove effects. Therapists reported patients
usually start to report any benefits, or adverse effects, by
a four- week review appointment. As gloves are intended
to be worn long-term, we selected a 12-week follow-up
as: allowing several weeks for glove tolerance to develop;
participants to experience effects of regular wear for up
to 2 months across a range of activities; and being a feas-
ible time-scale within the funding period. Therapists
highlighted the importance of ensuring participating
therapists understand that there is only low-level evi-
dence about arthritis gloves currently, it is unclear if
arthritis gloves are effective and therefore there is clin-
ical equipoise between arthritis and placebo gloves (i.e. a
placebo glove providing warmth is an ethically accept-
able alternative). This was considered essential as the
participating therapists all normally regularly provided
arthritis gloves as part of usual care. Accordingly, we
needed to facilitate therapists to overcome personal pref-
erences to provide arthritis gloves, be ethically willing to
enrol participants and provide placebo gloves in a trial,
be able to provide placebo gloves in a credible way and
not have prior expectations of the trial findings.
In the Arthritis Gloves (A-GLOVES) trial we aimed to
investigate, for people with RA and UIA with persistent
hand pain, the comparative clinical and cost-
effectiveness of providing arthritis gloves or placebo
gloves in addition to usual care.
Methods
Study design and ethics
The A-GLOVES trial was a pragmatic, multicentre,
investigator-blind, parallel-group randomised controlled
trial. The trial was conducted in rheumatology occupa-
tional therapy departments in 16 National Health Ser-
vice sites in England and Scotland. The trial was
approved by the North of Scotland National Research
Ethics Service Committee (REC reference 15/NS/0077).
The full protocol has been published [15].
Participants
Patients were eligible for inclusion if aged 18 years or
older, diagnosed with RA or UIA by a Rheumatology
consultant, with persistent pain in the PIPJs or MCPJs
causing at least one of: difficulty using the hands during
the day (for day wear); disturbed sleep (for night wear);
and limited ability to use the hands in the morning (for
night wear). We excluded patients diagnosed with other
inflammatory forms of arthritis affecting the hands (e.g.
psoriatic arthritis, gout, ankylosing spondylitis); severe
Raynaud’s disease, hand circulatory disturbances, hand
neuropathies or hand deformities; and any contraindica-
tions to glove-wear (e.g. eczema, broken skin). Partici-
pants should not previously have worn arthritis gloves.
We asked clinicians to identify potentially eligible pa-
tients during clinic visits or from therapy records. Pa-
tients were given an invitation letter and information
sheet. If interested they saw a research practitioner or
occupational therapist to discuss the trial, check eligibil-
ity, complete consent and study registration and receive
the baseline questionnaire (completed at home then
mailed to the research co-ordinating centre). Partici-
pants at screening who had recently received a steroid
injection or started oral steroids were deferred for 6
weeks after injection or drug start, and re-screened to
check for eligibility. Steroids could be a confounding
variable as they quickly improve hand symptoms [16].
Randomisation and blinding
Participants were randomly assigned (1:1) to the inter-
vention or control group, stratified by whether the par-
ticipant had a change in or new medication (DMARDs
or biologics) or not within the last 3 months, using per-
muted blocks of random sizes. Randomisation was com-
pleted by the Lancashire Clinical Trials Unit using
Sealed Envelope, a web-based central randomisation ser-
vice [17]. Participants were accumulated into both
groups from start of recruitment at each site. After ran-
domisation, allocation was unblinded to therapists deliv-
ering treatment. Participants were not blinded to group
allocation. The study was described as comparing the ef-
fects of two types of arthritis glove without divulging the
differences. Therapists were asked not to use the term
“compression gloves” to participants, in order to reduce
the risk of unblinding. Investigators and data manage-
ment staff were blinded to group allocation. Data were
analysed blinded to group allocation.
Interventions
Following randomisation, a referral was sent to the treat-
ing therapist, including group allocation. Gloves were
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fitted within 3 weeks, with a review appointment 2 to 4
weeks later to check for glove fit and any adverse events.
We tested the intervention gloves against placebo gloves,
in order to control for therapist time, attention and ef-
fects of receiving a medical device.
Participants in the intervention group, received cor-
rectly fitted three-quarter length finger Isotoner® gloves.
These are made of 80% nylon and 20% elastane. These
were selected for testing as they exert the highest level
of pressure of arthritis gloves available, at 23-32 mmHg
[8]. If compression is the mechanism of action of arth-
ritis gloves, then these gloves are more likely to lead to
effects being detected. Additionally, as these are the
most popular glove prescribed, testing Isotoner® gloves
reflects UK clinical practice [4]. The size range comfort-
ably fits hands up to 23.5 cm. MCPJs circumference.
Clinically, fitting Isotoner® gloves is not possible for
people with larger hands, as they are too tight and can
cause problems with pins and needles, numbness or
limit finger circulation (Fig. 1).
Participants in the control group received loose-fitting
three-quarter length finger Jobskin® classic oedema
gloves, made of 89% nylon and 11% elastane (placebo
gloves). When fitted correctly, these exert 15-25 mmHg
pressure [9]. However, these were fitted at least one size
too large and exerted no pressure. A focus group of RA
patients and expert rheumatology occupational thera-
pists chose the Jobskin® gloves, worn loosely, as a cred-
ible placebo glove because of sufficiently similar
appearance, material and warmth to the intervention
gloves. Additionally, Jobskin® gloves have the largest size
range available of arthritis glove makes prescribed in
clinical practice, accommodating hands up to 25.4 cm.
MCPJs circumference (Fig. 2).
At the first appointment, therapists measured the par-
ticipant’s MCPJs circumference to determine correct
glove size, visually checked appropriate fit and discussed
hand symptoms and function to determine an individual
wear regimen. Participants in either group, with hands
larger than 23.5 cm MCPJs circumference, were not fit-
ted with gloves as: the Isotoner® intervention gloves
would be too tight; and the largest size of placebo glove
insufficiently loose. Previous studies have reported diffi-
culties fitting gloves for those with large hands, with
some men reporting gloves being too short or small [5].
Most participants were issued with gloves for both hands
for day and night wear. However, some were provided
with only one glove (usually the dominant hand); or ad-
vised to wear gloves during the day or night only, i.e.
consistent with routine clinical practice. Participants
could wear gloves for most of the day and all night but
informed not to wear 24 h a day. Participants were given
booklets about hand self-management, including joint
protection [18], and hand exercise [19] and asked to do
hand exercises daily. We have made available the Arth-
ritis Gloves Occupational Therapist Provision Manual
describing the clinical protocol [20].
Participants continued to receive their Rheumatology
and Occupational Therapy department’s usual care. The
therapist could provide advice and training for up to 1 h
in joint protection and hand exercises when providing
gloves, (if needed, if the participant had not already re-
ceived these), reflecting clinical practice [4, 14]. Other
therapies could be provided.
Therapist training
Prior to the trial starting, we explained to therapists: the
existing research about arthritis gloves, the lack of good
quality and contradictory evidence for efficacy and ef-
fectiveness (clinical equipoise); the trial design to ensure
that they understood the reasons for testing arthritis
against placebo gloves and that warmth might be a con-
tributory mechanism, meaning placebo gloves are an ac-
ceptable comparator; and discussed any concerns about
providing placebo gloves. Therapists agreed to take part
following consideration of the trial design. Prior to at-
tending the trial training course, therapists were asked
to read two articles: a systematic review of arthritis
gloves [5] and an article exploring therapists’ views
about placebo splint provision within a trial [21]. They
then attended a one-day training course including: edu-
cation about randomised controlled trials; the A-Gloves
trial procedures, theoretical and practical training in
intervention and placebo glove fitting, in order to stand-
ardise the interventions; and a focus group about their
views of providing placebo gloves and personal, service
and research methodology issues in relation to their trial
participation [22]. Training explained the placebo effect
and emphasised: the importance of ensuring placebo
gloves were a loose fit so that no pressure was being
Fig. 2 Placebo Glove (loose-fitting Jobskin® classic oedema glove:
control group)
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applied, to avoid treatment contamination in the control
group; and how to answer control participants’ queries
related to the loose-fit of the placebo gloves, in order to
reduce the risk of control participant stopping glove-
wear. The accompanying glove provision manual de-
tailed procedures, glove-fitting and issues of providing
placebo gloves [20].
Data collection
Baseline data were collected using a postal self-
completed questionnaire. Randomisation occurred im-
mediately after receipt. Follow-up data were obtained
12-weeks post-randomisation by postal self-completed
questionnaire. After 1 week, participants were reminded
by e-mail, text or telephone to return the questionnaire.
If no response was received: after 2 weeks, participants
were sent a second copy of the questionnaire; and after
4 weeks they were contacted by telephone to obtain a
minimal data set, if possible.
Outcomes
The primary outcome measure, at 12-weeks post-
randomisation, was hand pain in the dominant hand
during the daytime when doing moderate hand activities
(e.g. housework, cooking, DIY, gardening), measured on
a numeric rating scale (NRS), with anchor points of no
pain (0) and severe pain (10). Minimal clinically import-
ant differences (MCID) for pain scales in RA are 1.1
points on a 0–10 NRS [23, 24]. Hand pain was selected
because it is the most common reason therapists provide
gloves and the symptom that patients most frequently
describe as benefiting from glove use [5, 6, 14].
Secondary outcomes were: non-dominant hand pain in
the day (0–10 NRS), dominant and non-dominant hand
pain at night (0–10 NRS); hand stiffness (0–10 NRS),
owing to a lack of predefined MCID this was considered
as ≥ 0.5 SD of mean baseline score [25, 26], i.e. in this
trial = 1.4 points); duration of hand early morning stiff-
ness (minutes); hand function (Measure of Activity
Performance-Hand, with higher scores denoting worse
hand function and Minimal Detectable Change (at 95%
confidence interval: MDC95) of 3.99 [27]; and Michigan
Hand Outcomes Questionnaire, with higher scores de-
noting better hand performance (apart from the hand
pain sub-scale), with an MCID of 13 points [28, 29]; and
disability (Health Assessment Questionnaire, with higher
scores denoting worse function [30]. Participants com-
pleted the EQ-5D-3L [31] as a measure of health benefit
for the economic evaluation and reported their use of
health and social care services at baseline and follow-up.
Additionally, at 12-week follow-up, we asked partici-
pants about: glove use; perceptions of glove-wear; and
new steroid prescription (injection or oral). Therapists
recorded glove provision, wear regimen and
occupational therapy provided as part of usual care on
standardised treatment logs. These were reviewed to
identify documentary evidence of glove provision, treat-
ment duration, and any adverse events. A detailed de-
scription of outcome measures was published in the trial
protocol [15]. Those questionnaire items developed spe-
cifically for the trial were constructed with the assistance
of the patient research partners (see study questionnaire
in Supplementary Materials).
Sample size
Using data from a pilot study [14], the mean change in
hand pain NRS (measured 4 weeks post-intervention)
was − 1.03 (SD 2.22). The 80% upper one-sided confi-
dence limit of the estimated SD, i.e. 2.48 was used. To
identify a MCID of 1.1-point, SD = 2.48, significance
level of 0.05 and 80% power, 80 participants per group
were required. Allowing for 22% missing 12-week pri-
mary outcome data, the target sample size was 205 ran-
domised participants.
Statistical and economic analysis
The analysis followed a pre-specified statistical analysis
plan and was by intention to treat, without imputation
of missing data. STATA V.14 was used [32]. Baseline
characteristics were described, overall and by group,
reporting mean (standard deviations), median (IQR) or
number (proportion), as appropriate. Primary effective-
ness analysis used linear regression to estimate an ad-
justed mean difference comparing dominant hand pain
during activity at 12 weeks (primary outcome) between
groups, adjusting for baseline scores and the stratifica-
tion variable (recent DMARD changes or not). Second-
ary analyses used appropriate modelling approaches
(multiple linear regression, logistic regression or ordinal
logistic regression), to estimate the effect of group allo-
cation on the other health outcomes at 12 weeks. A sen-
sitivity (per protocol) analysis omitted those who did not
receive gloves, or who self- reported being prescribed
steroids (oral or injection) during the trial. Data were
analysed by person and using dominant hand results, as
reported by the participant.
The economic analysis compared the costs and health
benefits of the gloves from a health and social care per-
spective. The primary economic analysis was based on
151 complete cases (i.e. participants with no missing
data). Sensitivity analysis explored the cost effectiveness
of arthritis gloves using the primary outcome measure,
in the sub-group of participants who were treated as per
the trial protocol (i.e. received gloves), and under alter-
native models of glove provision.
Intervention costs were estimated from individual pa-
tient treatment logs, for the number of gloves provided,
assuming one visit to an occupational therapist.
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Published unit costs were used to calculate total costs
for the intervention and healthcare utilisation in both
groups [33, 34]. Quality-adjusted life-years (QALYs)
were estimated from the EQ-5D-3L data, using an area
under the curve approach and published utility tariffs for
England [35]. Linear regression analysis was used to esti-
mate net QALYs and a generalised linear model with log
link and gamma family was used to estimate net costs for
the arthritis gloves compared to the placebo gloves, ad-
justed for baseline values and stratification variable. Boot-
strapping (n = 10,000 simulations) was used to estimate
the probability that arthritis gloves were cost-effective at
different willingness to pay thresholds (WTPTs).
Results
Recruitment
Figure 3 shows the patient flow through the trial. Be-
tween February 2016 and May 2017, 206 participants
were recruited and randomised, with 103 in the inter-
vention and 103 in the control groups. Within the inter-
vention group, 102 (99%) received Isotoner® gloves.
Within the control group, 88 (85%) received the placebo
gloves: 10 could not be fitted with gloves due to larger
hand size. At 12-week follow-up, data were received
from 84 (82%) in the intervention and 79 (77%) in the
control group. Those not fitted with gloves continued to
be followed up (Supplementary Table S1).
Participants
The median age of participants was 59 years, over 80%
were women and a third employed. Most were diag-
nosed with RA (86% control; 84% intervention). Median
time since diagnosis was 4 years and most (90%) were
prescribed DMARDs or biologic drugs (Table 1).
Glove provision and other therapy
Most participants (78%) received gloves within 3 weeks
of referral. All received gloves for their dominant hand,
and most in both groups for both hands (95/102 (93%)
intervention; n = 83/88 (94%) control). In both groups,
73% were recommended to wear gloves during the day.
Two-thirds of those responding at 12-weeks answered
the adherence items. For the remainder, glove wear was
unknown.
Self-reported glove wear was very similar between
groups for both hands at on average: 5 h during the
daytime on 5 days/ week; and 6 h at night for 5
nights/week (Table 2). On average, the intervention
group wore arthritis gloves somewhat less often at
night, compared to placebo glove wear in the control
group. At 12-week follow-up, there were no differ-
ences between groups in treatment duration or re-
ceiving steroids (Supplementary Table S2).
Primary outcome
At baseline both groups had moderate day-time levels of
dominant hand pain during activity (6.3 on the 0–10
NRS). At 12-week follow-up (n = 154), day-time domin-
ant hand pain reduced in both groups, with the interven-
tion group (n = 84) reducing slightly less than the
control group (n = 79) (1.0 versus 1.2 points). There was
no evidence of a difference between the intervention and
control gloves, after adjusting for the stratification vari-
able and baseline pain scores. The adjusted difference of
0.1 (favouring the control group) between groups (95%
CI − 0.47 to 0.67) was not statistically significant nor
clinically relevant (as the largest plausible positive effect
of the intervention gloves was 0.47 units, less than half
the MCID of 1.1 points) (Table 3). In the sensitivity (per
protocol) analysis (i.e. only those receiving the correct
gloves and who did not receive steroids), there was also
no statistically significant difference between groups (0.2
points, CI − 0.41 to 0.81; p = 0.51). No further analysis
adjusting for effects of glove-wear was conducted. As
there were no substantive differences in self-reported
frequency of dominant hand glove wear between groups,
this would have minimal impact on the estimated be-
tween group differences in the primary outcome.
Secondary outcomes
Both groups reported similar small levels of improve-
ment in hand symptoms of non-dominant hand pain on
activity, dominant and non-dominant hand pain at night,
hand stiffness, duration of morning hand stiffness, and
self-reported hand status, with no statistically significant
or clinically important differences between groups. Both
groups reported similar small improvements in hand
function and disability and with no statistically signifi-
cant or clinically relevant differences between groups
(Table 3).
In both groups, in those reporting perceived effects,
over 70% considered wearing gloves gave warmth and
comfort, were beneficial, and they would continue to
wear them (Table 2), supporting the qualitative study
[36]. Forty-one per cent in both groups thought they
helped them sleep better. Perceptions of glove-wear will
be reported in detail elsewhere.
Adverse events
In the intervention group, 47 (51%) reported an adverse
event compared to 29 (36%) in the control group, with
the most common in both groups being sleep disturb-
ance as the gloves made hands feel hot and itchy. The
intervention group reported more adverse events of pins
and needles, numbness or fingertip discolouration (26
events) than the control group (7 events) (Supplemen-
tary Table S3). Similar numbers discontinued glove-wear
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at the glove review appointment due to adverse events
(n = 7 (7%) control; n = 6 (6%) intervention, Fig. 3).
Cost-effectiveness
Both control and intervention groups had the same
health utility at baseline and accrued the same number
of QALYs during follow-up (Table 4).
Use of physiotherapy services was higher in the inter-
vention group (Supplementary Table 4). Costs associated
with healthcare services used are shown in Table 4. The
cost of providing placebo gloves is not included as these
would not normally be provided in the NHS. The main
difference in costs between groups was that of providing
the intervention gloves. The results of the incremental
cost-effectiveness analysis are reported in Table 5. The
intervention gloves are associated with higher costs but
comparable benefits to the placebo gloves and therefore
unlikely to be cost-effective. The gloves had an incre-
mental cost-effectiveness ratio (ICER) of £83,700 per
QALY gained. The intervention gloves have a probability
of 0.19–0.29 of being cost-effective if decision-makers
are willing to pay £20–30,000/QALY, respectively. Sensi-
tivity analyses confirmed that the intervention gloves are
not likely to be cost-effective (results reported in full in
Supplementary Table S5).
Discussion
These results showed that, for people with RA or UIA,
with moderate to severe hand pain, correctly fitted arth-
ritis gloves led to slight improvements in hand pain (day
or night), stiffness and function. However, wearing
loose-fitting placebo gloves led to similar slight benefits.
Fig. 3 Workwell CONSORT Flow Diagram
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Improvements from both types of gloves were at, or only
marginally above, the MCIDs for hand pain and hand
function, and below for hand stiffness, with no signifi-
cant or clinical differences between glove types. A high
number experienced adverse events: a half of those
wearing intervention and a third wearing control gloves.
Both gloves led to similar levels of reporting about dis-
rupted sleep. The intervention group experienced more
neurological and circulatory adverse events resulting
from the higher pressure applied by Isotoner® gloves.
Self-reported glove wear was similar between groups,
apart from the Isotoner® gloves being worn somewhat
less at night by the intervention group. These neuro-
logical and circulatory adverse events are more likely to
occur during prolonged periods of wear, such as at
night. There was also some more reporting of hands be-
coming hot and itchy at night (especially in hot weather)
in the intervention group. Both effects may have contrib-
uted to Isotoner® gloves being worn less often at night in
the intervention group. The arthritis gloves were not
cost-effective. Our results indicate arthritis gloves should
not be provided in routine clinical practice. This would
Table 1 Baseline participant characteristics of the intention-to-treat population (n = 206)
Control (n = 103) Intervention (n = 103)
Age (years): median (IQR) 60 (51,68) 58 (51,67)
Sex: female (%) 82 (80%) 84 (82%)
Diagnosis:
RA 89 (86%) 87 (84%)
UIA 14 (14%) 16 (16%)
Hand dominance:
Right (%) 92 (89%) 93 (90%)
Left (%) 9 (9%) 3 (3%)
Both (%) 2 (2%) 7 (7%)
Living status: Alone (%) 18 (17%) 19 (18%)
Living with children: yes (%) 10 (10%) 14 (14%)
Employment status:
Retired 50 (49%) 44 (43%)
Due to ill health 9 (9%) 18 (17%)
Other 41 (40%) 26 (25%)
Full-time work 24 (24%) 21 (20%)
Part-time work 13 (13%) 18 (17%)
Homemaker 9 (9%) 6 (6%)
Long-term sick 2 (2%) 7 (7%)
Unemployed 3 (3%) 3 (3%)
Self-employed 1 (1%) 3 (3%)
Student 0 (0%) 1 (1%)
Missing 1. (1%)
Symptom duration (months):
Median (IQR) 60 (24,168) 72 (18,174)
Diagnosis duration (months):
Median (IQR) 48 (10,144) 51 (8,168)
Medication regimen:
0 DMARDs a 10 11
1 DMARD 51 56
2 or more DMARDs 42 36
Biologics b 15 18
Started new/ changed DMARD or biologic in previous 3 months c: yes (%) 34 (33%) 34 (33%)
aDMARD Disease Modifying Anti-Rheumatic Drug; bparticipants were also prescribed a DMARD; cstratification variable
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lead to a considerable cost saving per year to Rheuma-
tology and Therapy departments, especially as glove
provision is a recurrent cost.
Whilst we did not test arthritis gloves in people with
other forms of hand arthritis, it would be reasonable to
assume similar results. Arthritis gloves are recom-
mended by arthritis charities and medical information
websites [37, 38] and commonly purchased by people
with hand arthritis. Such recommendations should be
reviewed. Health professionals should enable people with
hand arthritis to consider carefully, informed by the evi-
dence, whether to purchase gloves for themselves.
Even though the results demonstrated little benefit in
hand symptoms and hand function from wearing either
gloves, most people in both groups thought they were
beneficial and would continue to wear them. Both
groups thought gloves gave warmth, comfort and
support [36]. Arthritis gloves are thought to impact on
hand symptoms through applying pressure. The results
suggest that pressure is not an active ingredient in arth-
ritis gloves, as loose-fitting gloves led to similar results.
Perceived benefits were more likely due to warmth. A
previous trial concluded arthritis gloves and thermal
gloves had similar effects [6]. We hypothesize that the
tactile feedback from wearing gloves provided the re-
ported feelings of comfort and support and may sub-
consciously have reminded users to take more care of
their hand joints and subtly alter hand use during wear.
A similar effect was also suggested in a pilot trial of
thumb splints versus placebo thumb splints, which par-
ticipants liked equally [39].
As both gloves gave similar results, and participants
considered a main benefit was warmth [36], this suggests
ordinary light-weight three-quarter finger gloves, made
Table 2 Recommended glove-wear regimen, self-reported glove wear and glove benefit (12- week follow-up: n = 154)
Control (n = 70a): Intervention (n = 84): p
Recommended glove-wear regimen:
- Day time only 9 (13%) 20 (24%) 0.08
- Day and night 42 (60%) 41 (49%) 0.17
- Night-time only 19 (27%) 23 (27%) 0.97
Number of days gloves worn (day-time) per week in last 4 weeks: mean (SD)










Number of minutes gloves (worn (day-time) per day in last 4 weeks: Mean (SD)










Number of nights gloves worn per week in last 4 weeks: mean (SD)










Number of minutes gloves worn per night in last 4 weeks: Mean (SD)











- Gloves are beneficial 51 (73%) 61 (73%) 0.97
- Will continue to wear gloves 50 (72%) 59 (72%) 0.94
(n = 51) (n = 61)
- Gloves give warmth 41 (80%) 45 (74%) 0.41
- Gloves give comfort 38 (75%) 52 (85%) 0.15
- Sleep better 21 (41%) 25 (41%) 0.98
a10 control participants could not be fitted with gloves
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of nylon, cotton or wool (typically containing 5% elas-
tane), purchased from High Street or online stores,
could have similar effects. Therapists could recommend
patients purchase such gloves instead. The time saved
on glove provision could be used teaching hand exer-
cises and joint protection, both of which are effective in
reducing hand symptoms [40, 41]. Future research could
investigate whether people with arthritis consider wear-
ing ordinary light-weight gloves affects hand status.
This is the first randomised controlled trial to evaluate
arthritis glove-wear on daytime hand pain and function,
which are the main reasons for arthritis gloves being
prescribed currently in routine clinical practice. The re-
sults also confirmed previous smaller trials of full-finger
arthritis gloves that indicated there are no differences in
nocturnal pain and stiffness between wearing arthritis or
placebo gloves [5]. This trial demonstrates the import-
ance of testing widely used interventions, long

























difference e (95% CI)
p-
value
Dominant hand pain during
activity (0–10 NRS a)
6.3 (2.2) 5.1 (2.3) 1.2 6.3 (1.9) 5.3 (2.3) 1.0 0.1 (−0.47, 0.67) 0.72
Non-dominant hand pain
during activity (0–10 NRS)
5.6 (2.4) 4.5 (2.4) 1.1 5.7 (2.4) 4.3 (2.5) 1.4 −0.29 (0.94, 0.36) 0.38
Dominant hand pain during
rest (0–10 NRS)
5.2 (2.4) 3.8 (2.4) 1.4 4.6 (2.2) 3.9 (2.2) 0.7 0.29 (−0.32, 0.90) 0.35
Non-dominant hand pain
during rest (0–10 NRS)
4.7 (2.7) 3.6 (2.4) 1.1 4.4 (2.5) 3.3 (2.3) 1.1 −0.15 (−0.81, 0.51) 0.66
Dominant hand pain at
night
(0–10 NRS)
5.5 (2.8) 3.8 (2.6) 1.4 5.0 (2.5) 4.0 (2.5) 1.4 0.34 (−0.30,0.98) 0.30
Non-dominant hand pain at
night (0–10 NRS)
4.9 (2.9) 3.5 (2.7) 1.4 4.6 (2.8) 3.2 (2.5) 1.4 −0.32 (−0.98,0.35) 0.35




96.4 (226.7) 44.7 132.7
(269.8)
62.5 (53.0) 70.2 32 (−0.25,15.83) 0.37
Hand stiffness dominant
hand (0–10 NRS)
6.0 (2.6) 4.9 (2.6) 1.1 5.6 (2.9) 4.9 (2.9) 0.7 0.28 (−0.41,0.97) 0.42
Hand stiffness non-dominant
hand (0–10 NRS)
5.4 (2.9) 4.1 (2.7) 1.3 5.2 (2.9) 4.2 (2.9) 1.2 0.17 (−0.55,0.89) 0.64
Self-reported dominant
hand condition (1–5)
3.3 (0.7) 2.9 (0.8) 0.4 3.3 (0.7) 2.8 (1.0) 0.5 −0.18 (−0.77, 0.41) 0.56
Overall MAPHAND b (Hand
function) (0–3)
1.4 (0.6) 1.2 (0.6) 0.2 1.5 (0.5) 1.2 (0.6) 0.3 −0.05 (− 0.18, 0.07) 0.39
Overall HAQ c (0–3) 1.5 (0.7) 1.3 (0.7) 0.2 1.5 (0.6) 1.4 (0.8) 0.1 0 (−0.13,0.13) 0.99
Overall MHQ d (0–100) 49.8
(13.7)
57.2 (17.1) 7.4 49.3
(11.2)
57.0 (17.0) 7.9 0.37 (−3.45, 4.20) 0.85
- Overall hand function 42.8
(18.2)
50.3 (22.8) 7.5 43.6
(14.8)
54.6 (19.9) 11 3.49 (−2.05, 9.04) 0.22
- Activities of daily living 51.1.
(25.8)
59.7 (27.4) 8.6 51.2
(24.0)
59.0 (27.1) 7.8 −0.69 (−6.10; 4.71) 0.80
- Work 39.5
(23.7)
50.9 (23.1) 11.4 37.7
(19.9)
48.5 (26.0) 10.8 −1.30 (−7.28, 4.69) 0.67
- Pain 35.1
(25.8)
33.6 (23.4) 1.5 32.7
(24.6)
33.1 (23.4) 0.4 −0.07 (− 6.54, 6.40) 0.98
- Aesthetics 65.5
(19.5)
69.3 (21.4) 3.8 64.2
(18.5)
66.4 (22.7) 2.2 −2.18 (−8.08, 3.72) 0.47
- Satisfaction 35.3
(21.5)
48.5 (26.6) 13.2 32.3
(16.3)
48.4 (25.4) 16.4 1.95 (−4.99, 8.90) 0.58
aNRS Numeric Rating Scale, bMAPHAND Measure of Activity Performance – Hand, cHAQ Health Assessment Questionnaire, dMHQ Michigan Hand Questionnaire,
eadjusted between group difference – adjusted for stratification variable (change in DMARDS) and baseline score
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established in clinical practice, for which there is little
evidence. Identifying that arthritis gloves are not effect-
ive is a positive finding, as it enables clinical practice to
be evidence-based. Guidelines for the provision of hand
orthoses in arthritis should be updated. This trial also
provides sound evidence on which patients can base
their own decisions as to whether to purchase arthritis
gloves or ordinary gloves instead, as the latter would be
a considerable cost-saving, especially for those with lim-
ited incomes.
The strengths of our trial include the large sample
size, longer follow-up than previous trials (12 weeks
compared to 4 weeks) and full economic evaluation.
Recruiting from 16 rheumatology out-patient depart-
ments increased the likelihood of a representative sam-
ple. The trial design was developed with the PPI group’s
and clinical therapists’ inputs to ensure the control
intervention was credible and procedures feasible. We
ensured before the trial and during training that thera-
pists understood about current evidence and the clinical
equipoise between arthritis and placebo gloves, discussed
any ethical concerns, and they were willing and able to
credibly provide the placebo gloves. The self-reported
glove adherence rates in both groups were similar indi-
cating training supported therapists in placebo glove
provision. We tested the make of arthritis glove known
to provide the highest level of compression in order to
maximise the ability to detect any positive effects on
outcomes. It is therefore unlikely that any other make of
arthritis glove providing less compression would result
in different outcomes. The limitations of this trial are,
like many non-pharmacological trials, that therapists
could not be blinded. We did not have a third usual care
only control group. We considered it important to offer
treatment to all participants meeting trial criteria. An
objective independent clinical hand assessment (e.g. of
hand swelling and hand function) was not included.
However, our feasibility study indicated the main
changes were in pain, stiffness and daily hand function,
which are reliably measurable through patient reported
outcomes [14].
Conclusion
Arthritis gloves providing pressure and warmth and
loose-fitting placebo gloves providing warmth, had only
minimal effects on hand pain and function, with no dif-
ferences between glove types. Participants perceived
warmth as a main benefit from both gloves. Arthritis
gloves were not cost-effective. Given these results, thera-
pists could recommend patients buy ordinary three-
quarter finger length gloves. These are widely available,
would save health services money and be low-cost for
patients. These findings inform evidence-based treat-
ment choices for clinicians in specialist musculoskeletal
services, and community services, and for patients con-
sidering purchasing arthritis gloves.
Table 4 Mean (SD) health utility, Quality Adjusted Life Years (QALYs) and costs
Control Intervention
EQ-5D-3L Baseline n =
103










Utility (Mean, SD) 0.44 (0.37) 0.55 (0.55) 0.09 (0.27) 0.44 (0.34) 0.54 (0.31) 0.05 (0.26)
QALYs (Mean, SD) 0.12 (0.07) 0.12 (0.07)
Costs during follow-up (Mean, SD)
Outpatient £255 (268) (n = 78) £317 (333) (n = 82)
Primary and community
care
£59 (86) (n = 75) £66 (101) (n = 81)
Intervention £0 £129 (n = 78)
TOTALa £391 (543) (n = 75) £552 (464) (n = 78)
a Total cost includes inpatient admissions, day case visits, and A&E visits. The mean intervention cost is reported for participants with complete cost data.
Intervention cost comprised of actual number of compression gloves provided per participant costing £31.43/glove (NHS dispensing costs) and one visit to a
secondary care occupational therapist costing £65.85 (NHS reference costs)







Probability intervention is cost effective versus control if WTPT =
£20,000/ QALY £30,000/ QALY £60,000/ QALY




£83,700/QALY 0.19 0.29 0.44
Note: whole £ reported in table but ICERs calculated including pence
Covariates costs: pre-baseline costs, stratification variable
Covariates QALYs: baseline health status, stratification variable
ICER incremental cost-effectiveness ratio, WTPT willingness to pay threshold, ITT intention to treat
aat different willingness to pay thresholds, based on 10,000 bootstrap simulations
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